Success Stories: EB-1B Approval After RFE Achieved by NAILG for Scientist Transforming Cell-Based Therapeutic Research
Client’s Testimonial:
“Thank you very much for your help.”
On October 20th, 2025, we received another EB-1B (Outstanding Professors and Researchers) approval for a Research Fellow (Postdoctoral) in the Field of Cell Biology (Approval Notice).
General Field: Cell Biology
Position at the Time of Case Filing: Research Fellow (Postdoctoral)
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: October 20th, 2025
Processing Time: 1 year, 6 months, 12 days
Case Summary:
An EB-1B (Outstanding Researcher) petition was approved for a cell biology expert whose groundbreaking work in molecular imaging and immunotherapy has made lasting contributions to biomedical science. The petition, filed on April 8, 2024, received a Request for Evidence (RFE) on September 3, 2025, and was approved on October 20, 2025, after North America Immigration Law Group (NAILG) presented a detailed and compelling response that clearly demonstrated the petitioner’s record of sustained international recognition and research excellence.
The petitioner’s research bridges cell biology, molecular biochemistry, and immuno-oncology. His work focuses on developing biosensors for real-time cell imaging, investigating metabolic regulation in immune responses, and designing innovative therapeutic strategies for cancer treatment. Through this multifaceted approach, he has advanced the understanding of cellular dynamics, immune regulation, and tumor microenvironments, areas crucial to improving the diagnosis and treatment of complex diseases. His pioneering methods have been recognized by peers for their originality and far-reaching clinical implications.
Over the course of his career, the petitioner has published 14 peer-reviewed journal articles, including five first- or co-first-authored papers, which have collectively been cited 655 times by independent researchers worldwide. His studies have appeared in highly selective journals, reflecting both the quality and influence of his work. His research has become a foundation for further developments in metabolic pathway analysis and cell-based therapies, underscoring its substantial and ongoing impact.
In addition to his publication record, the petitioner has completed at least 25 peer reviews for leading international journals, further demonstrating his expertise and professional standing. His participation as a reviewer confirms that he is recognized by the global scientific community as a trusted authority capable of assessing complex research in cell biology, molecular therapy, and cancer immunology. This ongoing engagement with high-impact publications reflects both his leadership and his commitment to advancing scientific integrity and innovation.
NAILG’s strategic RFE response emphasized the petitioner’s sustained record of achievement, international influence, and major contributions to cancer biology and therapeutic development. By presenting comprehensive evidence of his scholarly impact, leadership in peer review, and influence on ongoing research worldwide, NAILG successfully established that he meets the rigorous standards for EB-1B classification. The petition’s approval reaffirms his position among the foremost researchers in his field and highlights NAILG’s continued success in securing immigration benefits for world-class scientists driving advances in biomedical innovation.